226 related articles for article (PubMed ID: 29080842)
21. Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway.
Maher JM; Dieter MZ; Aleksunes LM; Slitt AL; Guo G; Tanaka Y; Scheffer GL; Chan JY; Manautou JE; Chen Y; Dalton TP; Yamamoto M; Klaassen CD
Hepatology; 2007 Nov; 46(5):1597-610. PubMed ID: 17668877
[TBL] [Abstract][Full Text] [Related]
22. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells.
Kubo T; Kohno K; Ohga T; Taniguchi K; Kawanami K; Wada M; Kuwano M
Cancer Res; 1995 Sep; 55(17):3860-4. PubMed ID: 7641205
[TBL] [Abstract][Full Text] [Related]
23. Effect of stable inhibition of NRF2 on doxorubicin sensitivity in human ovarian carcinoma OV90 cells.
Manandhar S; Lee S; Kwak MK
Arch Pharm Res; 2010 May; 33(5):717-26. PubMed ID: 20512470
[TBL] [Abstract][Full Text] [Related]
24. ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells.
Bao L; Wu J; Dodson M; Rojo de la Vega EM; Ning Y; Zhang Z; Yao M; Zhang DD; Xu C; Yi X
Mol Carcinog; 2017 Jun; 56(6):1543-1553. PubMed ID: 28112439
[TBL] [Abstract][Full Text] [Related]
25. PERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy.
Salaroglio IC; Panada E; Moiso E; Buondonno I; Provero P; Rubinstein M; Kopecka J; Riganti C
Mol Cancer; 2017 May; 16(1):91. PubMed ID: 28499449
[TBL] [Abstract][Full Text] [Related]
26. MDR1 mediated chemoresistance: BMI1 and TIP60 in action.
Banerjee Mustafi S; Chakraborty PK; Naz S; Dwivedi SK; Street M; Basak R; Yang D; Ding K; Mukherjee P; Bhattacharya R
Biochim Biophys Acta; 2016 Aug; 1859(8):983-93. PubMed ID: 27295567
[TBL] [Abstract][Full Text] [Related]
27. 15-Deoxy-delta 12, 14-prostaglandin J2 induces upregulation of multidrug resistance-associated protein 1 via Nrf2 activation in human breast cancer cells.
Song NY; Kim DH; Kim EH; Na HK; Surh YJ
Ann N Y Acad Sci; 2009 Aug; 1171():210-6. PubMed ID: 19723058
[TBL] [Abstract][Full Text] [Related]
28. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer.
Homma S; Ishii Y; Morishima Y; Yamadori T; Matsuno Y; Haraguchi N; Kikuchi N; Satoh H; Sakamoto T; Hizawa N; Itoh K; Yamamoto M
Clin Cancer Res; 2009 May; 15(10):3423-32. PubMed ID: 19417020
[TBL] [Abstract][Full Text] [Related]
29. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.
Hayden A; Douglas J; Sommerlad M; Andrews L; Gould K; Hussain S; Thomas GJ; Packham G; Crabb SJ
Urol Oncol; 2014 Aug; 32(6):806-14. PubMed ID: 24837013
[TBL] [Abstract][Full Text] [Related]
30. Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway.
Gao AM; Ke ZP; Shi F; Sun GC; Chen H
Chem Biol Interact; 2013 Oct; 206(1):100-8. PubMed ID: 23994249
[TBL] [Abstract][Full Text] [Related]
31. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
32. Impact of Nrf2 on tumour growth and drug sensitivity in oncogenic K-ras-transformed cells in vitro and in vivo.
Shao J; Glorieux C; Liao J; Chen P; Lu W; Liang Z; Wen S; Hu Y; Huang P
Free Radic Res; 2018 Jun; 52(6):661-671. PubMed ID: 29621903
[TBL] [Abstract][Full Text] [Related]
33. Wogonin reversed resistant human myelogenous leukemia cells via inhibiting Nrf2 signaling by Stat3/NF-κB inactivation.
Xu X; Zhang X; Zhang Y; Yang L; Liu Y; Huang S; Lu L; Kong L; Li Z; Guo Q; Zhao L
Sci Rep; 2017 Feb; 7():39950. PubMed ID: 28150717
[TBL] [Abstract][Full Text] [Related]
34. Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance.
Cho JM; Manandhar S; Lee HR; Park HM; Kwak MK
Cancer Lett; 2008 Feb; 260(1-2):96-108. PubMed ID: 18036733
[TBL] [Abstract][Full Text] [Related]
35. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
Chian S; Li YY; Wang XJ; Tang XW
Asian Pac J Cancer Prev; 2014; 15(6):2911-6. PubMed ID: 24761924
[TBL] [Abstract][Full Text] [Related]
36. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
37. Naringin protects against anoxia/reoxygenation-induced apoptosis in H9c2 cells via the Nrf2 signaling pathway.
Chen RC; Sun GB; Wang J; Zhang HJ; Sun XB
Food Funct; 2015 Apr; 6(4):1331-44. PubMed ID: 25773745
[TBL] [Abstract][Full Text] [Related]
38. MRTF-A can activate Nrf2 to increase the resistance to doxorubicin.
Xu Y; Luo Y; Wang ZY; Li X; Zheng P; Zhang TC
Oncotarget; 2017 Jan; 8(5):8436-8446. PubMed ID: 28035058
[TBL] [Abstract][Full Text] [Related]
39. Protein kinase C isoenzymes, p53, accumulation of rhodamine 123, glutathione-S-transferase, topoisomerase II and MRP in multidrug resistant cell lines.
Utz I; Gekeler V; Ise W; Beck J; Spitaler M; Grunicke H; Hofmann J
Anticancer Res; 1996; 16(1):289-96. PubMed ID: 8615623
[TBL] [Abstract][Full Text] [Related]
40. Lysophosphatidate signaling stabilizes Nrf2 and increases the expression of genes involved in drug resistance and oxidative stress responses: implications for cancer treatment.
Venkatraman G; Benesch MG; Tang X; Dewald J; McMullen TP; Brindley DN
FASEB J; 2015 Mar; 29(3):772-85. PubMed ID: 25398768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
